Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GS,
I agree 100% that we either need more progress publicized by Abbott or a new licensee. Those two things will validate our product. Anything else from the company or a paid PR firm will do little for the stock price, IMO.
I have been really frustrated with the pullback in stock price since the ISOBM news. I expect that the company hoped to follow ISOBM more closely with news of a licensee. Well, it hasn't worked out yet and we still wait. Some are tired of waiting like Zolax. While I am frustrated, I remember messages from years ago expressing the same frustration waiting for the first licensee. The Abbott deal finally came through and I think a second deal will also.
I also remember a message that listed milestones that were finally achieved by Dr. Moro after longer than expected waits. One was the Abbott deal, another was getting the stock off the Pink Sheets. I can't remember the others, but the company has eventually done what they said they were going to do.
I think we should make a new list of expected milestones worth waiting for: a second licensee, beginning clinical trials, Abbott feasibility milestone, etc. I still think these things will happen eventually, so I will keep waiting.
HalfFull,
I agree that it didn't mention Abbott in the reports. I was hoping you had uncovered a connection that wasn't obvious. I did seem reasonable with the pregnancy restrictions, etc.
HalfFull,
I'm a little slow. From the links you provided, where do you get the connection to this being an Abbott test? I know you did a search of Abbott biomarkers and got those results. But I don't see anything mentioning Abbott.
Did you notice that the lung cancer study (in the link) was suspended?
Tommyb,
From my conversation with Terry (not to quote him though), my impression was that the the current funds on hand should be enough to last until revenues start coming in. The clause in the loan about another 3 million was looked at as more of an option than a requirement.
I feel okay about the loan unless a contract specialist tells us otherwise.
That's great! I scanned it too fast then. I will look again.
Thanks!
Isn't this just saying that the ROC curve was used to evaluate the accuracy of the test? This would be true for any test.
I scanned through the link information. There is a lot there. I didn't see anywhere that RECAF or AFP were mentioned so I don't think that we are involved in that. IMO, we should be. What do you think?
How did the Market Maker make any money today with no spread?
Is he buying for his own reserve?
Thanks Opportunity,
My call with Terry sounded similar to yours. One additional item that was re-emphasized was that Dr. Moro does want to minimize dilution of shares. They did enter into the financing agreement with the idea that the share price should appreciate and make it cheaper to use less shares. It was my impression that they were not pinning their hopes on the one PR about the ISOBM Conference. There should be more good news in the near future. No guarantees though.
quandong,
You seem to be thinking the glass is half empty. What if these shareholders anticipate that the company will finally/soon breakout and get the recognition it deserves?
opportunity,
Did you call today and ask your questions?
I called today and talked to Terry. It was the first time I have called. I found him to be easy to talk to. I would recommend anyone call if you have questions or concerns. There is even a toll-free number for those that were complaining about the cost some time ago. At least I think 866 is toll-free.
Gold,
I agree that the 10 day average is nearing the end. The right news tomorrow could still help.
A PR before ISOBM would have been nice. I was still thinking that an update of news that Tumor Biology has actually published Abbott research results, reference Tumor Biology (as an independent source) and maybe give us a slight bump up in credibility/validation.
What is you current thinking of when the next milestone payment will come from Abbott? Will we see a PR or only see it in the Quarterly Report?
Tell me if I'm wrong, but I'm still hoping for some kind of news by Wednesday. Weren't we thinking that would possibly happen to help Biocurex make the next loan payment with less shares?
I was thinking that could be as little as a repackaging of the news that Tumor Biology has published the joint Abbot/Biocurex research. Not sure if TB has done that yet though.
There could also be news of any new license agreement, but I'm not holding my breath.
Opportunity,
I share your frustration. I still have patience but tired of having to have it. I sent an e-mail to info@biocurex.com a week ago. My main comment was on the need for communication, true media coverage, and updates. I have not yet received a reply. I just sent a follow up e-mail.
Has anyone noticed that Tumor Biology has a Supplement 1 posted on their website for October 2007.
I don't remember seeing that before. It looks like it is the online version of the ISOBM Conference abstracts.
I found two of our write ups on page 92.
I have e-mailed the editor to get an update on when the hard copy version will be published.
Would this be a good time to reply to the writer of the Wall Street Journal article and mention that Abbott is working on a test which when used with the PSA test would provide much more accurate results. Please attach a link to one of Biocurex's recent news releasees.
I'm not a subscriber to the WSJ, but I will see what I can do if no one else will.
Half Full,
I just went to the Tumor Biology website, selected Journal Contacts, and e-mailed Dr. Rye directly. I interpreted his comment to mean the Tumor Biology Journal subscribers would receive the next publication in about three weeks.
I also e-mailed one of the other editors. Will let you know if I hear anything from him.
FYI, I was wondering when we could expect to see some information published from the September ISOBM Conference. I e-mailed the editors. Here is my e-mail and the response that I received.
From: me
To: Phil Rye
Subject: ISOBM Conference
Dr. Rye,
Can you say when the papers from last month's conference will be published? I am expecting it this month but wondered if you could be more specific.
Thank you.
Mr. XXXX
If you mean the abstracts, these were already published in the abstract booklet
at the time of the meeting.
If you mean when does the printed version get sent to individual journal subscribers, well, this may be a few more weeks yet due to some delivery problems (they were printed locally in Prague and extra copies have to be sent to our publisher in Switzerland for distribution to subscribers).
Hope this helps.
Phil D. Rye
<http://www.diagenic.com/>
________________________________
BioCurex and Abbott Jointly Present RECAF Results At International Cancer Congress
Monday September 24, 9:15 am ET
RICHMOND, British Columbia, Sept. 24, 2007 (PRIME NEWSWIRE) -- BioCurex Inc. (OTC BB:BOCX.OB - News) today announced two presentations to the International Society for Oncodevelopmental Biology and Medicine (ISOBM). The presentations document two RECAF studies involving joint initiatives with the University of Munich, Germany and Abbott....................
http://biz.yahoo.com/pz/070924/127201.html
It is great to hear that progress has been made towards a cancer test. This looks very promising, especially for Biocurex, BOCX.
Wait no longer! News is out! Check Yahoo News for BOCX
Please read back over recent news. The GE deal fell apart. Abbott kept the license and is scheduled to present on Monday.
Have you looked at Biocurex today? Up on high volume. Expecting good news next week.
I just remembered that you visited the BOCX board a few weeks ago.
mysscat,
I agree. We should make sure they are up on the latest developments. You would think that they would have realized by now that they need to keep up with this board. LOL
From Half Full's info on our research team, it made me hope that any results presented at ISOBM would all show effectiveness with a variety of cancer types.
Petra Stieber - experience with Breast Cancer
Stephen Frost - experience with Lung Cancer
Barry Dowell - experience with Colorectal Cancer
It would be great to show effectiveness across many cancer types. This would reinforce the company's previous results.
What do you think of this suggestion?
Assuming all of the regulars here have probably purchased a full position and are waiting on news, we do need to help get the word out. I don't recommend spamming other message boards. However, our due dillegence post #3564 could be updated. We could add the ISOBM link to presentations and make the connection clear that Abbott will be presenting on RECAF related results for the first time! The recent financing deal is big along with the company's stated plans for using the funds to perfect tests and increase efforts on therapeutics. Then there is the evidence of hiring new lab technicians. All of these things paint a pretty clear picture that good news is ahead.
I would suggest updating post 3564, or maybe even writing a summary post that would connect most of the dots for new investors. The great due dillegence is all here in the past two months of posts, it just takes some effort to piece it all together.
FYI, Tumor Biology has added a few more articles to their August Issue. Don't see any about RECAF yet. Maybe we will still get an early release.
Just wondering what everyone was expecting on the timing of potential news. From looking at Tumor Biology's previous issues, they had an August 2006 issue and an October 2006 issue. With the ISOBM Conference in September, wouldn't it be more likely that the September poster sessions would be written up in the October issue?
If that is the case, would the August issue be likely to include anything on RECAF? Apart from the Tumor Biology exposure, hopefully Biocurex will issue a PR before the Sept. Conference.
GS, after looking at it again, I would tend to agree that the RECAF work is in the sale to GE. I was confused about what was included by "invitro diagnostics".
The CEO of Abbott was just on CNBC. He did say that GE was better suited to consolidate the automated systems diagnostics market. I take that to mean the Architect systems.
The Abbott site also mentions Immuno Diagnostics. It sounds like this would be part of the core business being sold and where our RECAF work may reside.
I think we will just have to wait and see to know for sure.
Sounds like the in-vitro diagnostics and Point-of-Care diagnostics may not be our Abbott unit after all.
WSJ this evening: GE pushes into heathcare; nears deal to buy $2.9 billion Abbott Diagnostic
GE Nears Deal to Buy Abbott Division
By DENNIS K. BERMAN, KATHRYN KRANHOLD and AVERY JOHNSON
January 17, 2007 7:07 p.m.
General Electric Co. was last night nearing a deal to purchase the diagnostics division of Abbott Laboratories, people familiar with the matter said, as the conglomerate makes a deeper push into the world of healthcare and medical devices.
Exact details of GE's plans could not be learned Wednesday evening, and it is possible that GE may be purchasing a large part, but not all, of the Abbott unit. Through the first nine months of 2006, the division posted revenues of about $2.9 billion and operating profit of around $300 million, according to SEC filings, which represents about 18% of Abbott's revenues and just 7% of its operating profit.
The deal would broaden GE's $16 billion healthcare business, which has moved aggressively into healthcare information technology and molecular diagnostics in the past few years. The deal could mark GE's entry into "in vitro" diagnostics, which includes routine instrumentation and test kits. Abbott's core in vitro diagnostics business has been flat for several years.
In December, GE Chairman and Chief Executive Jeffrey Immelt indicated he was looking to grow the company's healthcare business and add new platforms through acquisitions. Mr. Immelt told analysts and investors, "We've always wanted to build a broader diagnostics company."
GE's main healthcare business remains manufacturing diagnostic equipment including ultrasound and x-ray machines, and more sophisticated screening equipment.
Mr. Immelt made his biggest strategic move in healthcare in 2004 when he paid more than $9 billion for Britain's Amersham, a bioscience and medical diagnostic firm. Through Amersham, GE entered the molecular diagnostic market. GE is now developing molecular agents that are injected into the blood stream and target specific diseases. The agents then show up during screenings indicating that a patient has a particular cancer or disease. Diagnostics related to breast cancer has been among GE's key areas of focus.
Abbott's diagnostics business is driven by growth in two segments: glucose monitoring for diabetics and molecular tests for diseases like breast cancer. Sara Michelmore, an analyst at Cowen & Co., forecasts 2006 diagnostics revenues around $3.9 billion. The core business accounts for some $2.5 billion of that revenue, and is flat compared to 2005. She says the molecular products grew year-over-year by about 20%, while the glucose-monitoring piece grew 9%. The diagnostics division has been a bit of a thorn in Abbott's side since 1999, when regulators found one of its manufacturing facilities to violate FDA regulations. The plant in question made chemical kits used to test for diseases, and despite Abbott's attempts to resolve the matter, a consent decree continued to hamper it for several years.
Within the past year Abbott acquired Guidant's vascular wing for $4.1 billion and Kos Pharmaceuticals for $3.7 billion. It spun off low-growth hospital products unit Hospira in 2004. That same year, it beefed up the glucose-monitoring side of the diagnostics business with a $1.2 billion deal for TheraSense.
Other similar deals of late have brought in hefty revenue multiples. In June, Siemens AG paid $5.3 billion for Bayer's diagnostics division, which had about $1.8 billion in 2005 sales. Siemens also bought Diagnostic Products last year for $1.86 billion, a major premium on that company's roughly $480 million in 2005 sales.
Abbott spokeswoman Melissa Brotz declined to comment.
Write to Dennis K. Berman at dennis.berman@wsj.com1, Kathryn Kranhold at kathryn.kranhold@wsj.com2 and Avery Johnson at avery.johnson@WSJ.com3
CSFB = Credit Suisse First Boston
Kag,
Thanks for your response about the patent application timing.
As for the first milestone payment guessing contest, I'll say Sept. 15, 2006 but will be looking for it May 12th.
Kag,
I'm a lurker/shareholder and have enjoyed reading this board for almost a year. Your post raised a question in my mind that may have been discussed before but I don't remember. You mentioned Abbott and possible patent application for a new assay. Where would patent application fit into the timeline in relation to a first milestone payment? I just thought that would be a major signal (understatement) if it happened before the milestone payment. So my guess is that the milestone payment and announcement would come first.
mcd